Nov 30, 2022 08:30AM
Nov 17, 2022 08:30AM
Nov 9, 2022 07:00AM
Nov 7, 2022 08:30AM
Nov 7, 2022 08:30AM
Nov 3, 2022 08:30AM
Nov 3, 2022 08:30AM Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Women’s Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection
Nov 1, 2022 08:30AM
Oct 25, 2022 08:33AM
Oct 25, 2022 08:30AM
Oct 24, 2022 08:32AM
Oct 24, 2022 08:30AM
Oct 20, 2022 07:17AM
Oct 20, 2022 07:00AM SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal
Sep 9, 2022 08:30AM
Sep 8, 2022 08:32AM
Sep 8, 2022 08:30AM
Sep 1, 2022 08:30AM
Aug 15, 2022 07:00AM
Aug 4, 2022 08:31AM
Aug 4, 2022 08:30AM SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
Aug 1, 2022 08:31AM
Aug 1, 2022 08:30AM
May 17, 2021 08:30AM
May 14, 2021 08:30AM
May 11, 2021 08:30AM
Apr 30, 2021 08:00AM
Apr 20, 2021 08:00AM SCYNEXIS to Present Two Ibrexafungerp (Brexafemmeᵀᴹ) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting
Mar 29, 2021 08:20AM
Mar 2, 2021 07:32AM
Mar 2, 2021 07:30AM
Feb 25, 2021 04:15PM
Feb 23, 2021 08:15AM
Feb 23, 2021 08:15AM
Feb 17, 2021 08:15AM SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China
Feb 17, 2021 08:15AM
Jan 5, 2021 04:04PM
Dec 7, 2020 08:03AM
Dec 7, 2020 08:00AM
Nov 6, 2020 08:45AM
Oct 21, 2020 08:30AM
Mar 11, 2020 08:18AM SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update
May 24, 2018 09:23AM
Oct 7, 2016 09:21AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All